EX-99.1 2 ex033122991pressrelease.htm EX-99.1 Document
Exhibit 99.1
Performant Financial Corporation Announces Financial Results for First Quarter 2022
Livermore, Calif., May 9, 2022 - Performant Financial Corporation (Nasdaq: PFMT), (the "Company"), a leading provider of technology-enabled audit, recovery, and related analytics services in the United States with a focus in the healthcare payment integrity services industry, today reported the following financial results for its first quarter ended March 31, 2022:

First Quarter Financial Highlights

•Total revenues of $27.1 million, compared to revenues of $31.4 million in the prior year period.
•Healthcare revenues of $23.4 million, compared to $13.3 million in the prior year period, an increase of 76%
•Net loss of approximately $1.7 million, or $(0.02) per diluted share, compared to net loss of $4.4 million, or $(0.08) per diluted share, in the prior year period.
•Adjusted net loss was $1.1 million, or $(0.02) per diluted share, compared to adjusted net loss of $2.8 million, or $(0.05) per diluted share, in the prior year period.
•Adjusted EBITDA of $0.3 million, compared to $(0.2) million in the prior year period.

First Quarter 2022 Results
Total revenues in the first quarter were $27.1 million, a decrease of $4.3 million, or 14% from revenues of $31.4 million in the prior year period. Excluding the $14.5 million that we reported in the first quarter of 2021 from our shuttered Recovery markets business, total revenues grew over 60% year-over-year. Healthcare revenues in the first quarter of 2022 were $23.4 million, an increase of $10.1 million, or 76%, from revenues of $13.3 million in the prior year period. Within Healthcare, claims-based services revenue in the first quarter of 2022 was $9.1 million, while revenue from eligibility-based services in the first quarter was $14.2 million.
“In the first quarter we reported our strongest ever first quarter for healthcare revenues driven by the continued growth from our fully implemented SOWs as well as the contribution from some of the 33 program implementations that we've announced over the past five quarters,” stated Simeon Kohl, President of Performant. “In addition, we were awarded the HHS OIG IDIQ Contract for Medical Review and Consultative Services as well as the award for Region 2 of the Medicare Fee for Service Recovery Audit Program, but we anticipate a delay before the latter contract kicks off as the award is currently under review by CMS related to the incumbent contractor’s protest.”
Recovery revenues in the first quarter were $0.1 million, a decrease of $14.4 million, or 99%, from revenues of $14.5 million in the prior year period. Revenues from our Customer Care / Outsourced Services in the first quarter were $3.6 million, flat when compared to the prior year period.
Net loss for the first quarter was $1.7 million, or $(0.02) per share on a diluted basis, compared to a net loss of $4.4 million, or $(0.08) per share on a diluted basis, in the prior year period. Adjusted net loss for the first quarter was $1.1 million, or $(0.02) per share on a diluted basis, compared to adjusted net loss of $2.8 million, or $(0.05) per diluted share, in the prior year period. Adjusted EBITDA for the first quarter was $0.3 million as compared to $(0.2) million in the prior year period.
As of March 31, 2022, the Company had cash, cash equivalents, and restricted cash of approximately $19.6 million.
“Given our achievements in the first quarter and known opportunities ahead of us that we believe we can execute upon, we are quite pleased with how we are tracking toward both the current year expectations and more importantly, our long term goals. We remain optimistic about improving trends in core utilization and the return to normal from COVID but acknowledge that COVID variant uncertainty and uncertainty in the macro affairs of an ever connected world may impact utilization rates. That said, we are pleased to amend our current views on Healthcare revenue and believe that we can achieve $92-$96MM in Healthcare market revenues in 2022, with Customer Care market revenues being flat to slightly down. We are leaving our EBITDA guidance intact at $2-$4 million for 2022 until we can gain further clarity on the timing and ramp-speed of the RAC Region 2 contract to provide a more informed update,” stated Rohit Ramchandani, Senior Vice President of Finance and Strategy at Performant.


Note Regarding Use of Non-GAAP Financial Measures
In this press release, to supplement our consolidated financial statements, the Company presents adjusted EBITDA, adjusted net income (loss), and adjusted net income (loss) per diluted share. These measures are not in accordance with accounting principles generally accepted in the United States of America (US GAAP) and accordingly reconciliations of adjusted EBITDA and adjusted net income (loss) to net income (loss) determined in accordance with US GAAP are included in the “Reconciliation of Non-GAAP Results” table at the end of this press release. We have included adjusted EBITDA and adjusted net income (loss) in this press release because they are key measures used by our management and board of directors to understand and evaluate our core operating performance and trends and to prepare and approve our annual budget. Accordingly, we believe that adjusted EBITDA and adjusted net income (loss) provide useful information to investors and analysts in understanding and evaluating our operating results in the same manner as our management and board of directors. Our use of adjusted EBITDA and adjusted net income (loss) has limitations as an analytical tool and should not be considered in isolation or as a substitute for analysis of our results as reported under US GAAP. In particular, many of the adjustments to our US GAAP financial measures reflect the exclusion of items, specifically interest, tax and depreciation and amortization expenses, equity-based compensation expense and certain other non-operating expenses, that are recurring and will be reflected in our financial results for the foreseeable future. In addition, these measures may be calculated differently from similarly titled non-GAAP financial measures used by other companies, limiting their usefulness for comparison purposes.
Earnings Conference Call
The Company will hold a conference call to discuss its first quarter 2022 results today at 5:00 p.m. Eastern. A live webcast of the call may be accessed on the Investor Relations section of the Company’s website at investors.performantcorp.com. The conference call is also available by dialing 844-826-3033 (domestic) or 412-317-5185 (international).
A replay of the call will be available on the Company's website or by dialing 844-512-2921 (domestic) or 412-317-6671 (international) and entering the passcode 10166578. The telephonic replay will be available approximately three hours after the call, through May 16, 2022.
About Performant Financial Corporation
Performant is a leading provider of technology-enabled audit, recovery, and analytics services in the United States with a focus in the healthcare payment integrity industry. Performant works with healthcare payers through claims auditing and eligibility-based (also known as coordination-of-benefits) services to identify improper payments. The Company engages clients in both government and commercial markets. The Company also has a call center which serves clients with complex consumer engagement needs. Clients of the Company typically operate in complex and highly regulated environments and contract for their payment integrity needs in order to reduce losses on improper healthcare payments.
Powered by a proprietary analytic platform and workflow technology, Performant also provides professional services related to the recovery effort, including reporting capabilities, support services, customer care and stakeholder training programs meant to mitigate future instances of improper payments. Founded in 1976, Performant is headquartered in Livermore, California.


Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's outlook for revenues, net income (loss), and adjusted EBITDA in 2022 and beyond. These forward-looking statements are based on current expectations, estimates, assumptions and projections that are subject to change and actual results may differ materially from the forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the material adverse impact of the COVID-19 pandemic on the Company's business, results of operations and financial condition as well as on the business operations and financial performance of many of its customers, that the Company faces a long period to implement a new contract which may result in the incurring of expenses before the receipt of revenues from new client relationships, that downturns in domestic or global economic conditions and other macroeconomic factors could harm the Company’s business and results of operations, that the Company may not have sufficient cash flows from operations to fund ongoing operations and other liquidity needs, that the high level of revenue concentration among the Company's largest customers and any termination in the Company’s relationship with any of its significant clients would result in a material decline in revenues, that many of the Company's customer contracts are subject to periodic renewal, are not exclusive, do not provide for committed business volumes and may be changed or terminated unilaterally and on short notice, that the Company may not be able to manage its potential growth effectively, that the Company faces significant competition in all of its markets, that limitations on the scope of the Company's audit activity under its claims audit contracts may reduce revenue opportunities, that the U.S. federal government accounts for a significant portion of the Company's revenues, that the Company’s indebtedness could adversely affect its business and financial condition and could reduce the funds available for other purposes and the failure to comply with covenants contained in its credit agreement could result in an event of default that could adversely affect its results of operations, that future legislative and regulatory changes may have significant effects on the Company's business, that failure of the Company's or third parties' operating systems and technology infrastructure could disrupt the operation of the Company's business and the threat of breach of the Company's security measures or failure or unauthorized access to confidential data that the Company possesses. More information on potential factors that could affect the Company's financial condition and operating results is included from time to time in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's annual report on Form 10-K for the year ended December 31, 2021 and subsequently filed reports on Forms 10-Q and 8-K. The forward-looking statements are made as of the date of this press release and the Company does not undertake to update any forward-looking statements to conform these statements to actual results or revised expectations.
Contact Information
Richard Zubek
Investor Relations
925-960-4988
investors@performantcorp.com

PERFORMANT FINANCIAL CORPORATION AND SUBSIDIARIES
Consolidated Balance Sheets
(In thousands, except per share amounts)
 March 31,
2022		December 31,
2021
 (Unaudited) 
Assets
Current assets:
Cash and cash equivalents$17,432 $17,347 
Restricted cash2,203 2,203 
Trade accounts receivable, net of allowance for doubtful accounts of $29 and $—, respectively
19,837 20,808 
Contract assets8,875 8,113 
Prepaid expenses and other current assets3,941 3,077 
Income tax receivable3,085 3,159 
Total current assets55,373 54,707 
Property, equipment, and leasehold improvements, net15,306 15,708 
Goodwill47,372 47,372 
Right-of-use assets2,760 3,235 
Other assets965 963 
Total assets$121,776 $121,985 
Liabilities and Stockholders’ Equity
Current liabilities:
Current maturities of notes payable, net of unamortized debt issuance costs of $13 and $11, respectively
$612 $489 
Accrued salaries and benefits5,935 8,476 
Accounts payable1,191 1,124 
Other current liabilities1,762 3,732 
Contract liabilities773 634 
Estimated liability for appeals and disputes1,471 1,190 
Lease liabilities1,528 1,862 
Total current liabilities13,272 17,507 
Notes payable, net of current portion and unamortized debt issuance costs of $392 and $416, respectively
18,858 19,084 
Lease liabilities1,601 1,803 
Other liabilities1,174 1,168 
Total liabilities34,905 39,562 
Commitments and contingencies (note 3 and note 4)
Stockholders’ equity:
Common stock, $0.0001 par value. Authorized, 500,000 shares at March 31, 2022 and December 31, 2021 respectively; issued and outstanding 73,144 and 69,281 shares at March 31, 2022 and December 31, 2021, respectively
7 7 
Additional paid-in capital139,783 133,662 
Accumulated deficit(52,919)(51,246)
Total stockholders’ equity86,871 82,423 
Total liabilities and stockholders’ equity$121,776 $121,985 


PERFORMANT FINANCIAL CORPORATION AND SUBSIDIARIES
Consolidated Statements of Operations
(In thousands, except per share amounts)
(Unaudited)
 Three Months Ended  
March 31,
 20222021
Revenues$27,083 $31,390 
Operating expenses:
Salaries and benefits20,439 24,090 
Other operating expenses8,131 10,356 
Total operating expenses28,570 34,446 
Loss from operations(1,487)(3,056)
Interest expense(155)(1,346)
Loss before provision for income taxes(1,642)(4,402)
Provision for income taxes31 37 
Net loss$(1,673)$(4,439)
Net loss per share
Basic$(0.02)$(0.08)
Diluted$(0.02)$(0.08)
Weighted average shares
Basic69,873 54,813 
Diluted69,873 54,813 

PERFORMANT FINANCIAL CORPORATION AND SUBSIDIARIES
Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
 Three Months Ended  
March 31,
 20222021
Cash flows from operating activities:
Net loss$(1,673)$(4,439)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Loss (gain) on disposal of assets and impairment of long-lived assets(17)636 
Depreciation and amortization1,102 1,016 
Right-of-use assets amortization475 507 
Stock-based compensation558 649 
Interest expense from debt issuance costs24 369 
Changes in operating assets and liabilities:
Trade accounts receivable971 2,616 
Contract assets(762)(283)
Prepaid expenses and other current assets(864)117 
Income tax receivable74 60 
Other assets(2)85 
Accrued salaries and benefits(2,541)799 
Accounts payable67 458 
Contract liabilities and other current liabilities(1,815)(114)
Estimated liability for appeals and disputes281 3,359 
Lease liabilities(536)(591)
Other liabilities 7 (422)
Net cash (used in) provided by operating activities(4,651)4,822 
Cash flows from investing activities:
Purchase of property, equipment, and leasehold improvements(700)(826)
Proceeds from sale of certain recovery contracts— — 
Net cash used in investing activities(700)(826)
Cash flows from financing activities:
Repayment of notes payable(125)(863)
Debt issuance costs paid(2)— 
Taxes paid related to net share settlement of stock awards— (23)
Proceeds from exercise of warrants5,563 — 
Net cash provided by (used in) financing activities5,436 (886)
Net increase in cash, cash equivalents and restricted cash85 3,110 
Cash, cash equivalents and restricted cash at beginning of period19,550 18,296 
Cash, cash equivalents and restricted cash at end of period$19,635 $21,406 
Reconciliation of the Consolidated Statements of Cash Flows to the
Consolidated Balance Sheets:
Cash and cash equivalents$17,432 $19,203 
Restricted cash2,203 2,203 
Total cash, cash equivalents and restricted cash at end of period$19,635 $21,406 
Supplemental disclosures of cash flow information:
Cash paid for income taxes$1 $432 
Cash paid for interest$176 $977 

PERFORMANT FINANCIAL CORPORATION AND SUBSIDIARIES
Reconciliation of Non-GAAP Results
(In thousands, except per share amount)
(Unaudited)
 Three Months Ended  
March 31,
 20222021
(in thousands)
Adjusted EBITDA:
Net income (loss)$(1,673)$(4,439)
Provision for income taxes31 37 
Interest expense (1)
155 1,346 
Stock-based compensation558 649 
Depreciation and amortization1,102 1,016 
Impairment of long-lived assets— 636 
Severance expenses (4)
142 — 
Non-core operating expenses (5)
4 511 
Adjusted EBITDA$319 $(244)


 Three Months Ended  
March 31,
 20222021
(in thousands)
Adjusted Net Income (Loss):
Net income (loss)$(1,673)$(4,439)
Stock-based compensation558 649 
Amortization of intangible assets (2)
— 59 
Amortization of debt issuance costs (3)
24 369 
Impairment of long-lived assets— 636 
Severance expenses (4)
142 — 
Non-core operating expenses (5)
4 511 
Tax adjustments (6)
(200)(611)
Adjusted net income (loss)$(1,145)$(2,826)


Three Months Ended  
March 31,
20222021
(in thousands)
Adjusted Net Income (Loss) Per Diluted Share:
Net income (loss)$(1,673)$(4,439)
Plus: Adjustment items per reconciliation of adjusted net income (loss)528 1,613 
Adjusted net income (loss)$(1,145)$(2,826)
Adjusted net income (loss) per diluted share$(0.02)$(0.05)
Diluted average shares outstanding 69,873 54,813 

PERFORMANT FINANCIAL CORPORATION AND SUBSIDIARIES
Reconciliation of Non-GAAP Results
(In thousands, except per share amount)
(Unaudited)
We are providing the following preliminary estimates of our financial results as follows:
Three Months EndedNine Months EndingYear Ended Year Ending
March 31, 2022December 31, 2022December 31, 2021December 31, 2022
ActualEstimate ActualEstimate
Adjusted EBITDA:
Net income (loss)$(1,673)$ (3,827) to (5,827)$(10,288)$ (5,500) to (7,500)
Provision for income taxes31 (381) to 71962 (350) to 750
Interest expense (1)
155 845 to 1,34511,313 1,000 to 1,500
Stock-based compensation558 1,442 to 2,4422,640 2,000 to 3,000
Depreciation and amortization1,102 3,648 to 4,6485,188 4,750 to 5,750
Impairment of long-lived assets— — 636 — 
Severance expenses (4)
142 (42) to 3582,160 100 to 500
Non-core operating expenses (5)
4 (4)2,588 — 
Gain on sale of certain recovery contracts (7)
— — (2,403)— 
Adjusted EBITDA$319 $ 1,681 to 3,681$11,896 $ 2,000 to 4,000

(1)Represents interest expense and amortization of debt issuance costs related to our Credit Agreement and Prior Credit Agreement.
(2)Represents amortization of intangibles related to the acquisition of Performant by an affiliate of Parthenon Capital Partners in 2004.
(3)Represents amortization of debt issuance costs related to our Credit Agreement and Prior Credit Agreement.
(4)Represents severance expenses incurred in connection with a reduction in force for our non-healthcare recovery services.
(5)Represents professional fees related to strategic corporate development activities.
(6)Represents tax adjustments assuming a marginal tax rate of 27.5% at full profitability.
(7)Represents gain on the sale of certain non-healthcare recovery contracts in 2021.

PERFORMANT FINANCIAL CORPORATION AND SUBSIDIARIES
Reconciliation of Non-GAAP Results
(In thousands, except per share amount)
(Unaudited)
We are providing the following historical breakdown of the quarterly and annual revenue contributions under the new contribution breakdowns of our healthcare revenue results for the three months ended March 31, 2022, and for the years ended December 31, 2021 and 2020:
For the Three Months Ended
March 31, 2022
(in thousands)
Eligibility-based$14,215 
Claims-based9,149 
Healthcare Total23,364 
Recovery118 
Customer Care / Outsourced Services3,601 
Total$27,083 


For the Three Months EndedFor the Year Ended
March 31, 2021June 30, 2021September 30, 2021December 31, 2021December 31, 2021
(in thousands)
Eligibility-based$7,911 $11,577 $12,727 $16,061 $48,276 
Claims-based5,375 7,025 7,280 9,498 29,178 
Healthcare Total13,286 18,602 20,007 25,559 77,454 
Recovery14,491 11,091 5,490 2,333 33,405 
Customer Care / Outsourced Services3,613 3,149 3,085 3,687 13,534 
Total$31,390 $32,842 $28,582 $31,579 $124,393 


For the Three Months EndedFor the Year Ended
March 31, 2020June 30, 2020September 30, 2020December 31, 2020December 31, 2020
(in thousands)
Eligibility-based$10,949 $11,292 $13,480 $14,126 $49,847 
Claims-based6,575 3,301 4,086 4,739 18,701 
Healthcare Total17,524 14,593 17,566 18,865 68,548 
Recovery24,265 16,167 15,443 17,521 73,396 
Customer Care / Outsourced Services4,099 3,025 3,219 3,650 13,993 
Total$45,888 $33,785 $36,228 $40,036 $155,937